Ardent Health Partners (NYSE:ARDT) Price Target Lowered to $18.00 at Mizuho

Ardent Health Partners (NYSE:ARDT) had its price target decreased by Mizuho from $19.00 to $18.00 in a research note published on Wednesday morning,Benzinga reports. Mizuho currently has an outperform rating on the stock.

Several other research analysts also recently commented on ARDT. JPMorgan Chase & Co. restated a “neutral” rating and issued a $20.00 target price on shares of Ardent Health Partners in a research note on Tuesday, December 17th. Royal Bank of Canada dropped their target price on Ardent Health Partners from $23.00 to $21.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 4th. Morgan Stanley dropped their target price on shares of Ardent Health Partners from $23.50 to $22.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 21st. Stephens reaffirmed an “overweight” rating and set a $22.00 price objective on shares of Ardent Health Partners in a research report on Tuesday, April 1st. Finally, Truist Financial cut their price objective on shares of Ardent Health Partners from $22.00 to $21.00 and set a “buy” rating for the company in a research report on Monday, January 6th. Two investment analysts have rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Ardent Health Partners currently has an average rating of “Buy” and a consensus target price of $20.58.

Ardent Health Partners Trading Down 2.9 %

Ardent Health Partners stock opened at $11.76 on Wednesday. Ardent Health Partners has a 12-month low of $11.60 and a 12-month high of $20.72. The company has a current ratio of 1.91, a quick ratio of 1.78 and a debt-to-equity ratio of 0.78. The firm’s fifty day moving average is $13.86 and its 200 day moving average is $15.77.

Ardent Health Partners (NYSE:ARDT) last posted its quarterly earnings results on Wednesday, February 26th. The company reported $0.81 earnings per share for the quarter, topping analysts’ consensus estimates of $0.50 by $0.31. The firm had revenue of $1.61 billion for the quarter, compared to analyst estimates of $1.48 billion. As a group, research analysts predict that Ardent Health Partners will post 1.23 EPS for the current fiscal year.

Institutional Trading of Ardent Health Partners

A number of institutional investors have recently added to or reduced their stakes in the stock. Point72 Asia Singapore Pte. Ltd. purchased a new position in Ardent Health Partners in the fourth quarter valued at about $27,000. US Bancorp DE purchased a new position in Ardent Health Partners in the 4th quarter valued at approximately $31,000. R Squared Ltd purchased a new position in Ardent Health Partners in the 4th quarter valued at approximately $37,000. BNP Paribas Financial Markets acquired a new position in Ardent Health Partners during the third quarter worth $42,000. Finally, New York State Common Retirement Fund purchased a new stake in Ardent Health Partners during the fourth quarter worth $48,000.

Ardent Health Partners Company Profile

Ardent Health Partners, Inc owns and operates a network of hospitals and clinics that provides a range of healthcare services in the United States. It operates acute care hospitals, including rehabilitation hospitals and surgical hospitals. The company was founded in 2001 and is based in Brentwood, Tennessee.